



E • M • C • T • O

European Multidisciplinary Conference
in Thoracic Oncology 2013

emcto.org

EUROPEAN MULTIDISCIPLINARY CONFERENCE IN THORACIC ONCOLOGY

Programme Book

andec-group.com

Lugano
Switzerland

9-11 May 2013

Organisers



CONFERENCE PROGRAMME

Thursday, 9 May 2013

13:00/ 13:15	Official welcome and opening of the Conference	AUDITORIUM A
13:15/ 13:45	Keynote lecture Chair: Keith Kerr, Aberdeen, UK	AUDITORIUM A
13:15	Intratumour heterogeneity and evolution: Opportunities for therapy Charles Swanton, London, UK	
13:45/ 15:15	Molecular pathology of non-small cell lung cancer Chairs: Keith Kerr, Aberdeen, UK and Ken O'Byrne, Dublin, Ireland	AUDITORIUM A
13:45	Introduction	
13:50	Molecular characteristics of lung adenocarcinoma Keith Kerr, Aberdeen, UK	
14:10	Molecular characteristics of lung squamous cell carcinoma Martin Edelman, Baltimore, MD, US	
14:30	Challenges of biomarker testing with IHC and FISH Lukas Bubendorf, Basel, Switzerland	
14:50	Opportunities, limitations and implications of new genome sequencing Antonio Marchetti, Chieti, Italy	
15:10	Conclusions / Q&A	
15:15	Coffee Break	
15:45/ 17:15	Diagnostic work-up Chairs: Gaetano Rocco, Naples, Italy and Johann Vansteenkiste, Leuven, Belgium	AUDITORIUM A
15:45	Introduction	
15:50	Getting tissue in the era of molecular treatment Christophe Doods, Leuven, Belgium	
16:10	PET-CT for lung nodules: Opportunities and pitfalls Malene Fischer, Copenhagen, Denmark	
16:30	Reliable lung nodule identification during VATS David R. Jones, Charlottesville, VA, US	

16:50 When to treat without tissue confirmation
Sara Ramella, Rome, Italy

17:10 Conclusions / Q&A

17:30/18:30 **European Thoracic Oncology Platform (ETOP)**
Society Symposium
Please refer to page 39 for details

AUDITORIUM A

18:30/19:30 **Welcome Reception**

Friday, 10 May 2013

08:00/09:00 **Early and locally advanced disease**
Chairs: Kevin Franks, Leeds, UK
and Paul Van Schil, Edegem, Belgium

AUDITORIUM A

08:00 T1bN0M0 in a "marginally operable" patient: Surgery
Paul Van Schil, Edegem, Belgium

08:30 T1bN0M0 in a "marginally operable" patient: SABR
Kevin Franks, Leeds, UK

08:00/09:00 **Advanced disease**
Chairs: Federico Cappuzzo, Livorno, Italy
and Jean-Paul Sculier, Brussels, Belgium

ROOM B

08:00 When to stop TKI treatment in NSCLC with driver mutation?
- Pneumology
Jean-Paul Sculier, Brussels, Belgium

08:30 When to stop TKI treatment in NSCLC with driver mutation?
- Medical Oncology
Federico Cappuzzo, Livorno, Italy

08:00/09:00 **Poster Discussion: Biology and targeted therapy**
Chairs: Thierry Berghmans, Brussels, Belgium
and Nicola Normanno, Naples, Italy

ROOM C

70PD - Effect of enobosarm, a selective androgen receptor modulator, in non-small cell lung cancer (NSCLC) patients with muscle wasting in a phase IIb trial
Mitchell Steiner, Memphis, TN, US

40PD - Small cell lung cancer and hyponatremia: Interim results from a prospective, observational, global registry
Andrew Makin, Uxbridge, UK

08:00 Discussant abstracts 70PD and 40PD
Thierry Berghmans, Brussels, Belgium

08:10 Questions to Discussant

	71PD - Reversible epidermal growth factor receptor tyrosine kinases inhibitors (rEGFR-TKIs), erlotinib or gefitinib, compared to chemotherapy (CHT) in previously treated metastatic non small cell lung cancer (NSCLC) patients (pts): A meta-analysis Alessia Pochesci, Rome, Italy	
	72PD - Impact of EGFR status on the presence of liver metastases (LM) from non-small cell lung cancer (NSCLC) and survival implications Eduardo Castañón Alvarez, Pamplona, Spain	
	26PD - Foretinib (GSK1363089), a multikinase inhibitor of MET and VEGFs, overcomes resistance to bevacizumab in an in vivo model of acquired bevacizumab resistance Mian Xie, Guangzhou, China	
08:20	Discussant abstracts 71PD, 72PD and 26PD Kostas Syrigos, Athens, Greece	
08:30	Questions to Discussant 24PD - Metabolomic profile of lung cancer patients Leonor Puchades-Carrasco, Valencia, Spain	
	25PD - Circulating micro-RNA profiling in patients with advanced non-squamous non small-cell lung cancer receiving bevacizumab/erlotinib first-line treatment followed by platinum-based chemotherapy at disease progression (SAKK19/05) Markus Joerger, St. Gallen, Switzerland	
	2PD - Isolation and characterization of circulating tumour cells in advanced squamous-cell carcinoma of the lung Cecilia Bozzetti, Parma, Italy	
08:40	Discussant abstracts 24PD, 25PD and 2PD Nicola Normanno, Naples, Italy	
08:50	Questions to Discussant	
09:15/ 10:30	Early-drug development in lung cancer	AUDITORIUM A
	Chairs: Alex A. Adjei, Buffalo, NY, US and Enriqueta Felip, Barcelona, Spain	
09:15	Challenges in designing phase I trials in the era of targeted therapies Alex A. Adjei, Buffalo, NY, US	
09:35	Phase I studies in the broad cancer population vs selected patients Benjamin Besse, Villejuif, France	
09:55	How should we utilize biomarkers in phase I trials? Enriqueta Felip, Barcelona, Spain	
10:15	Panel Discussion	
10:30	Coffee Break	

11:00/12:30 **Early stage NSCLC (Stages I & II)** **AUDITORIUM A**
Chairs: Lucio Crinò, Perugia, Italy
and Gaetano Rocco, Naples, Italy

- 11:00 Introduction
- 11:05 Treatment of octogenarians
Gaetano Rocco, Naples, Italy
- 11:25 Sublobar resection
Henrik J. Hansen, Copenhagen, Denmark
- 11:45 SABR for centrally located tumours
Suresh Senan, Amsterdam, Netherlands
- 12:05 Is lobectomy by VATS or by robot the surgical standard?
Thomas Schmid, Innsbruck, Austria
- 12:25 Conclusions / Q&A

11:00/12:30 **Proffered Papers: Systemic therapy** **ROOM B**
Chair: Luis Paz-Ares, Seville, Spain
Co-Chair: Martin Reck, Grosshansdorf, Germany

- 11:00 **670** - Are first-line platinum-based (PT) regimens improving survival in comparison with non-platinum (NPT) chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC)? A meta-analysis (MA) of randomised trials
Thierry Berghmans, Brussels, Belgium
- 11:10 **680** - Efficacy, safety and tolerability results from a phase IV, open-label, single arm study of 1st-line gefitinib in Caucasian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC)
Jean-Yves Douillard, St. Herblain, France
- 11:20 **360** - 99mTc-etarfolatide (EC20) imaging to identify NSCLC patients likely to benefit from vintafolide (EC145) treatment
Weal Harb, Lafayette, IN, US
- 11:30 Discussant abstracts 670, 680 and 360
Elisabeth Quoix, Strasbourg, France
- 11:45 **690** - Molecular follow up of an Italian cohort of EGFR mutated patients progressing after treatment with oral tyrosine kinase inhibitors
Bruno Gori, Rome, Italy
- 11:55 **220** - Rebiopsy in TKI-resistance; A retrospective analysis
Justine Kuiper, Amsterdam, Netherlands
- 12:05 **650** - Her2 in non-small cell lung carcinomas
Zoran Gatalica, Phoenix, AZ, US
- 12:15 Discussant abstracts 690, 220 and 650
Luis Paz-Ares, Seville, Spain

12:30/13:00 **Lunch & Poster Display session**
Please refer to page 27 for details

13:00/14:00 **Treatment strategies in NSCLC: Shaping clinical practice** **ROOM B**
Roche Satellite Symposium
Please refer to page 39 for details

14:00/15:30 **Stage III NSCLC** **AUDITORIUM A**
Chairs: Wilfried Eberhardt, Essen, Germany
and Walter Weder, Zurich, Switzerland

14:00 Introduction

14:05 Is surgery indicated in persistent N2 after neoadjuvant treatment?
Walter Weder, Zurich, Switzerland

14:25 Is post-operative RT necessary in completely resected patients with mediastinal involvement?
Cecile Le Pechoux, Villejuif, France

14:45 Integrating targeted treatment in a neoadjuvant approach: Opportunities and risks
Enriqueta Felip, Barcelona, Spain

15:05 How to improve cure rates of chemoradiotherapy for stage III treatment in European populations
Dirk De Ruyscher, Maastricht, Netherlands

15:25 Conclusions / Q&A

14:15/15:30 **Proffered Papers: Diagnosis and pathology** **ROOM B**
Chair: Stephen Finn, Dublin, Ireland
Co-Chair: Giulia Veronesi, Milan, Italy

14:15 **10** - The LungPath Study - Optimising the pathological diagnosis of lung cancer
Paul Cane, London, UK

14:25 **230** - Serum microrna as a diagnostic test for early lung cancer
Giulia Veronesi, Milan, Italy

14:35 Discussant abstracts 10 and 230
Stephen Finn, Dublin, Ireland

14:45 **660** - EGFR mutated patients (pts): Different pattern and outcome of metastatic bone disease (MBD) and brain metastasis (BM)?
Lizza Hendriks, Maastricht, Netherlands

14:55 Discussant abstract 660
Benjamin Besse, Villejuif, France

15:05 **150** - Volumetric computer tomography screening for lung cancer: Three rounds of the NELSON trial
Nanda Horeweg, Rotterdam, Netherlands

15:15 Discussant abstract 150
Giulia Veronesi, Milan, Italy

15:25 General Q&A

15:30/15:50 **San Salvatore Foundation Award** **AUDITORIUM A**
Chairs: Luigi Butti, Lugano, Switzerland
and Rolf A. Stahel, Zurich, Switzerland

15:50 Coffee Break

16:10/17:10 **Immunotherapy of non-small cell lung cancer** **AUDITORIUM A**
Chairs: Solange Peters, Lausanne, Switzerland
and Rolf A. Stahel, Zurich, Switzerland

16:10 Vaccination approaches to NSCLC
Johan Vansteenkiste, Leuven, Belgium

16:25 Novel immunotherapy treatment approaches in non-small cell lung cancer
Naiyer Rizvi, New York, NY, US

16:45 Combination therapies in non-small cell lung cancer
Martin Reck, Grosshansdorf, Germany

17:00 Conclusions / Q&A

This session is kindly supported by an unrestricted educational grant from BMS

17:10/18:20 **SCLC and Thymoma** **AUDITORIUM A**
Moderators: Cecile Le Pechoux, Villejuif, France
and Enrico Ruffini, Turin, Italy

17:10 Thymoma treatment – A European overview
Enrico Ruffini, Turin, Italy

17:25 Thymoma biology
Nicholas Girard, Lyon, France

17:40 Controversies in surgical treatment of thymoma
Walter Klepetko, Vienna, Austria

17:55 Ongoing trials in SCLC and what we can expect
Corinne Faivre-Finn, Withington, Manchester, UK

18:10 Conclusions / Q&A

17:10/18:00 **Mesothelioma** **ROOM B**
Chairs: Paul Baas, Amsterdam, Netherlands
and Isabelle Opitz, Zurich, Switzerland

17:10 What did we learn from multimodality treatment?
Isabelle Opitz, Zurich, Switzerland

17:25 Is there a standard surgical approach within multimodality treatment?
Laureano Molins, Barcelona, Spain

17:40 New insights in mesothelioma biology:
Are there clinical implications?
Emanuela Felley-Bosco, Zurich, Switzerland

17:55 Conclusions / Q&A
Paul Baas, Amsterdam, Netherlands

Saturday, 11 May 2013

08:00/ 09:00	Radical approach to oligometastatic disease Chairs: Elisabeth Quoix, Strasbourg, France and Johan Vansteenkiste, Leuven, Belgium	AUDITORIUM A
08:00	A patient with synchronous isolated adrenal gland metastasis and right upper lobe T1aN2 adenocarcinoma Virginie Westeel, Besancon, France	
08:30	A patient with T2aN2 adenocarcinoma and one brain and one contralateral rib metastasis Dirk De Ruyscher, Maastricht, Netherlands	
<hr/>		
08:00/ 09:00	Locally advanced disease Chairs: Max Dahele, Amsterdam, Netherlands and Lorenzo Spaggiari, Milan, Italy	ROOM B
08:00	Re-irradiation following a local recurrence in stage III NSCLC Max Dahele, Amsterdam, Netherlands	
08:30	Salvage therapy in locally advanced NSCLC progressive after neoadjuvant treatment Lorenzo Spaggiari, Milan, Italy	
<hr/>		
08:00/ 09:00	Poster Discussion: Risk factors and combined modality therapy Chairs: Mina Gaga, Athens, Greece and Walter Klepetko, Vienna, Austria	ROOM C
	38PD - Current role of VATS in the diagnosis of a mediastinal lymphadenopathy of unknown etiology Felice Lo Faso, Ravenna, Italy	
	57PD - Neoadjuvant chemoradiotherapy for locally advanced nonsmall cell lung cancer Alper Toker, Istanbul, Turkey	
	58PD - VATS lobectomy after induction therapy for lung cancer: A safe and effective method Yi C. Wu, Taoyuan, Taiwan	
	59PD - Pre- and intraoperative photodynamic therapy in locally advanced central NSCLC Andrey Akopov, Saint Petersburg, Russian Federation	
08:00	Discussant abstracts 38PD, 57PD, 58PD and 59PD Walter Klepetko, Vienna, Austria	
08:15	Questions to Discussant	
	123PD - Prognostic and predictive factors in patients with lung cancer and brain metastases Bozena Jochymek, Gliwice, Poland	
	122PD - Age specific risk assessment in senior lung cancer patients Nazar Lukavetsky, Lviv, Ukraine	

96PD - Pattern and survival of lung metastasis in young breast cancer patients: A single centre experience
Ajay Gogia, New Delhi, India

08:30 Discussant abstracts 123PD,122PD and 96PD
Mina Gaga, Athens, Greece

08:45 Questions to Discussant

**09:10/
10:40** **Personalised treatment
of advanced disease**

AUDITORIUM A

Chairs: Solange Peters, Lausanne, Switzerland
and Jean-Paul Sculier, Brussels, Belgium

09:10 Introduction

09:15 EGFR TKI
Solange Peters, Lausanne, Switzerland

09:35 ALK/ROS1
Silvia Novello, Orbassano-Torino, Italy

09:55 Other targets in adenocarcinoma
Ken O'Byrne, Dublin, Ireland

10:15 Other targets in squamous cell carcinoma
Martin Reck, Grosshansdorf, Germany

10:35 Conclusions / Q&A

Financial support for this Educational Session has been provided by Lilly

**09:10/
10:40** **Proffered Papers: Combined
modality therapy**

ROOM B

Chair: Cecile Le Pechoux, Villejuif, France
Co-Chair: Paul Van Schil, Edegem, Belgium

09:10 **480** - Treatment of multiple primary lung cancers (MLPC)
with stereotactic ablative radiotherapy (SABR)
Gwendolyn Griffioen, Amsterdam, Netherlands

09:20 **500** - Predictors for radiation pneumonitis after SABR for
high-risk lung tumours
Eva Bongers, Amsterdam, Netherlands

09:30 **560** - Outcomes of concurrent chemo-radiotherapy for
large-volume stage III NSCLC
Max Dahele, Amsterdam, Netherlands

09:40 Discussant abstracts 480, 500 and 560
Cecile Le Pechoux, Villejuif, France

09:55 **950** - Surgical treatment of 549 patients with lung
metastases from colorectal carcinoma. Initial results of a
prospective Spanish study
Laureano Molins, Barcelona, Spain

10:05	370 -18-F FDG PET total glycolytic volume in thymic epithelial neoplasms evaluation: An easily reproducible image biomarker Luca Bertolaccini, Cuneo, Italy	
10:15	490 - Lungtransplantation in early stage carcinoma of the explanted lung - Is it a cure for the cancer? Thomas Klikovits, Vienna, Austria	
10:25	Discussant abstracts 370 and 490 Paul Van Schil, Edegem, Belgium	
10:40	Coffee Break	
11:00/ 12:00	What are the requirements for a thoracic oncology centre? Chairs: Enriqueta Felip, Barcelona, Spain and Jean Paul Sculier, Brussels Belgium	AUDITORIUM A
11:00	Screening Giulia Veronesi, Milan, Italy	
11:20	Radiotherapy Daniel Zips, Dresden, Germany	
11:40	Surgery Bernward Passlick, Freiburg, Germany	
12:00/ 13:00	Advances and perspectives for 2013 onwards Chairs: Enriqueta Felip, Barcelona, Spain and Rolf A. Stahel, Zurich, Switzerland	AUDITORIUM A
12:00	What is emerging in biomarker testing? Nicola Normanno, Naples, Italy	
12:20	What is on the horizon for personalised treatment? Luis Paz-Ares, Seville, Spain	
12:40	What are the consequences for the design of clinical trials? Tony S.K. Mok, Hong Kong, China	
13:00/ 13:30	Keynote Lecture Chair: Enriqueta Felip, Barcelona, Spain	AUDITORIUM A
13:00	Combining knowledge towards personalized treatment by a multidisciplinary team Rolf A. Stahel, Zurich, Switzerland	
13:30/ 13:45	Closing remarks	AUDITORIUM A
13:45	Light lunch	

SOCIETY AND INDUSTRY SATELLITE SYMPOSIA PROGRAMMES

Thursday, 9 May 2013

17:30/ 18:30	SOCIETY SYMPOSIUM European Thoracic Oncology Platform (ETOP) Chairs: Solange Peters, Lausanne, Switzerland and Rolf A. Stahel, Zurich, Switzerland	AUDITORIUM A
17:30	Lungscape Rolf A. Stahel, Zurich, Switzerland	
17:45	BELIEF Rafael Rosell, Badalona, Spain	
18:00	EMPHASIS Solange Peters, Lausanne, Switzerland	
18:15	Emerging projects Solange Peters, Lausanne, Switzerland	



Friday, 10 May 2013

13:00/ 14:00	INDUSTRY SATELLITE SYMPOSIUM Roche Treatment strategies in NSCLC: Shaping clinical practice Chairs and Panel: Solange Peters, Lausanne, Switzerland and Martin Reck, Grosshansdorf, Germany	ROOM B
12:50	Welcome	
12:55	Getting to maintenance: Spotlight on anti-VEGF therapy Martin Reck, Grosshansdorf, Germany	
13:10	Q&A Panel	
13:20	A clear perspective on the role of EGFR TKIs Solange Peters, Lausanne, Switzerland	
13:40	Q&A Panel	
13:50	Close	

